NCT01033019View on ClinicalTrials.gov

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
Interventions
DRUG

LDE225 0.75%

0.75% cream

DRUG

Vehicle

matching placebo cream to 0.75% LDE225 cream

Trial Locations (4)

1090

Novartis Investigative Site, Vienna

4102

Novartis Investigative Site, Woolloongabba

4217

Novartis Investigative Site, Benowa

A-8036

Novartis Investigative Site, Graz

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY